Laura Bordone is a distinguished leader in the pharmaceutical sector, currently serving as the Director of Clinical Development at Ionis Pharmaceuticals, Inc. With a robust focus on RNA-targeted therapeutics, Laura is at the forefront of pioneering clinical initiatives aimed at addressing rare diseases. Her role...
Laura Bordone is a distinguished leader in the pharmaceutical sector, currently serving as the Director of Clinical Development at Ionis Pharmaceuticals, Inc. With a robust focus on RNA-targeted therapeutics, Laura is at the forefront of pioneering clinical initiatives aimed at addressing rare diseases. Her role as Co-Project Team Leader for Phase 3 activities for donidalorsen exemplifies her expertise in clinical drug development, where she is responsible for critical elements such as protocol design, regulatory interactions, and patient recruitment.
Laura's extensive experience in clinical affairs is complemented by her adeptness in navigating complex regulatory landscapes, ensuring that all submissions are meticulously prepared and aligned with industry standards. Her strategic oversight in site selection and data collection has been instrumental in optimizing trial efficiency and enhancing patient safety assessments. Moreover, Laura's commitment to statistical analysis and data integrity underpins her approach to delivering reliable and impactful results.
In addition to her technical acumen, Laura is recognized for her exceptional leadership skills, fostering collaboration among cross-functional teams to drive project success. Her ability to communicate complex scientific concepts effectively has facilitated strong relationships with stakeholders, ensuring that the advancements in RNA-targeted therapies are well-documented and disseminated through publications and presentations. With a solid foundation in drug discovery, high-throughput screening, and laboratory research, Laura Bordone continues to make significant contributions to the field, positioning Ionis Pharmaceuticals as a leader in innovative therapeutic solutions.
